NHS NEL
Demonstration Formulary
 
back
6 Endocrine system

 

 

 

06-01-02-03 DPP4 inhibitors (gliptins)

Sitagliptin
First Choice

To be used in line with NICE

First line treatment option where a DPP-4 inhibitor is indicated.


No significant clinical benefit when used in combination with Insulin – avoid using together

Link  MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis

Green View adult BNF  View SPC online  View childrens BNF
Alogliptin Vipidia®
Formulary

In line with NICE No significant clinical benefit when used in combination with Insulin – avoid using together 

Link  MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis

Green View adult BNF  View SPC online  View childrens BNF
Linagliptin
Formulary

In line with NICE
Linagliptin has no significant clinical benefit or renoprotective effect in patients with CKD.

Sitagliptin should be used first line at the appropriate renal dose
where a DPP4 inhibitor is indicated


No significant clinical benefit when used in combination
with Insulin – avoid using together

Link  MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis

Green View adult BNF  View SPC online  View childrens BNF
Sitagliptin Januvia®
Non Formulary
Link  MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis

Black View adult BNF  View SPC online  View childrens BNF